Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-11T00:41:05.738Z Has data issue: false hasContentIssue false

Should we be worried about glaucoma? Why the prevalence of glaucoma is variably reported

Published online by Cambridge University Press:  01 October 2009

Anthea Worley
Affiliation:
Centre for Allied Health Evidence, University of South Australia, City East Campus, North Tce, Adelaide, SA 5000, Australia
Karen Grimmer-Somers*
Affiliation:
Centre for Allied Health Evidence, University of South Australia, City East Campus, North Tce, Adelaide, SA 5000, Australia
*
Correspondence to: Karen Grimmer-Somers, Centre for Allied Health Evidence, University of South Australia, City East Campus, North Tce, Adelaide, SA 5000, Australia. Email: Karen.Grimmer-Somers@unisa.edu.au
Rights & Permissions [Opens in a new window]

Abstract

Aim

This paper reports on a recent review of the prevalence of glaucoma, and identifies factors that impact on its variable reporting.

Background

Glaucoma is a recognized chronic degenerative health problem worldwide, in which approximately two-thirds of sufferers are undiagnosed. Therefore it is important to better quantify glaucoma prevalence to plan adequate resources for effective risk screening, diagnosis, management and prevention. Accurate prevalence data also assist in determining the nature of relationships between glaucoma and putative risks.

Methods

A comprehensive search of peer-reviewed databases was conducted to identify and critically appraise secondary evidence published between 2002 and 2007. Glaucoma definitions, prevalence, incidence and risk factor data were extracted and compared in the context of their population descriptors.

Findings

There was no standard definition of glaucoma or standard population descriptors (age, ethnicity, country) utilized by either the primary studies included in the secondary evidence or as inclusion criteria in the secondary evidence. Prevalence for glaucoma of between 1–4% was commonly reported. Despite this, the influence of age and ethnicity on glaucoma prevalence within specific populations was repeatedly highlighted. There was consistency across studies of the decreased risk of white (European) populations compared with other ethnic groups. There was an exponential increase in prevalence of glaucoma over decades of increasing age. There were limited Australian data; however, prevalence of open-angle glaucoma is comparable with international figures. There is a clear need for worldwide agreement on standard epidemiological descriptors of glaucoma, using standard population frameworks, terminology and age groups.

Type
Research
Copyright
Copyright © Cambridge University Press 2009

Introduction

Glaucoma is recognized worldwide, as a chronic degenerative health problem, expected to affect 60.5 million people by 2010 (South-East Asia Glaucoma Interest Group (SEAGIG), 2003; US Preventive Services Task Force (USPSTF), 2005). Glaucoma affects individuals through the full age span. It is estimated that up to two-thirds of people with glaucoma are undetected (USPSTF, 2005). Once established, glaucoma is progressive and usually relentless, and the damage to the eye is irreversible. The importance of good vision in maintaining good general health cannot be underestimated and therefore early detection of glaucoma is essential to global eye health.

Despite its worldwide recognition, there is no definition of glaucoma that is consistently used across the literature. Bathija (1998) cited in Rolim de Moura et al. (Reference Rolim de Moura, Paranhos and Wormald2007: 2) suggests that the lack of agreement on the definition of glaucoma is one of the underlying reasons for inconsistency in glaucoma diagnosis. This lack of consistency in glaucoma diagnosis impacts on the accuracy of reported prevalence rates. There is, however, broad agreement that any form of glaucoma should be described as a progressive optic neuropathy with characteristic visual field loss, optic disc and nerve fibre degeneration. According to Burr et al. (Reference Burr, Azuara-Blanco and Avenell2004: 2) ‘Glaucoma describes a group of eye diseases in which there is progressive damage to the optic nerve characterised by specific structural abnormalities of optic nerve head and associated patterns of visual field loss’. Accurate estimations of the prevalence of glaucoma are important to assist in planning resources for services, and to promote effective risk screening, diagnosis, management and prevention of glaucoma. Having accurate prevalence data also assist in understanding associations between glaucoma and putative risks.

This paper describes the findings of one aspect of a large metasynthesis of the literature, which distilled best evidence for the diagnosis, risk-identification and management of glaucoma. This paper reports on the prevalence of glaucoma internationally, and the factors that are associated with prevalence reports. Australian prevalence data are considered in the context of the internationally reported data.

Methodology

Objective: To report findings of a recent metasynthesis regarding international glaucoma prevalence and identify factors that impact on its variable reporting.

Justification of study design: This paper reports on aspects of findings from a wide-ranging systematic overview of the secondary literature that addressed the detection, diagnosis, prevention and management of glaucoma. Preliminary scoping of the literature for this question highlighted a large volume of secondary evidence published over the past five years. The majority (approximately 68%) of the secondary evidence identified during preliminary scoping was published between 2006 and 2007, and thus the risk of overlooking recent key primary literature within the secondary evidence was considered low. Thus, only secondary evidence was considered for this review, as it provided an efficient mechanism to synthesize the large amount of available primary literature, which had already been summarized in different forms by other reviewers. The metasynthesis included the highest level of evidence on the National Health and Medical Research Council (NHMRC) evidence hierarchy, comprising clinical guidelines, meta-analysis and systematic reviews.

Literature inclusion criteria:

  • Publication date 2002–2007 (inclusive).

  • English language publications only. Sensitivity testing regarding information published in languages other than English has shown that English language reviews represent a robust view of the available evidence base in health areas (Moher et al., Reference Moher, Klassen, Schulz and Berlin2000; 2003; Møller and Jennions, Reference Møller and Jennions2001).

  • Level I evidence from the NHMRC hierarchy of evidence (NHMRC, 2005) (clinical guidelines, meta-analysis and systematic reviews) that was available, unless a lack of Level I evidence in any one area of the review necessitated drawing on specific Level II or Level III evidence (recent primary studies).

  • Human studies only, inclusive of all age, gender, nationality and location.

Exclusion criteria:

  • Primary literature unless otherwise indicated.

  • Clinical guidelines in which glaucoma was not the primary focus (for instance, glaucoma occurring as a result of suffering another health condition).

  • Literature dealing exclusively with cost-based outcomes.

  • Non-English language publications.

  • Literature only available in abstract form or conference presentations.

  • Publications not available through all available library resources.

Search strategy

A comprehensive electronic library database search was undertaken (outlined in Appendix 1). Given the wealth of current secondary evidence that appeared relevant, secondary research evidence pertaining to the detection, diagnosis, management and prevention of glaucoma was identified first.

The library database searches were supplemented by pearling and manual searching of reference lists and other resources to identify all relevant secondary evidence. Pearling (also called secondary evidence searching) occurs when the reference list of a study, which has been included in a systematic review, is checked for other references that might also be relevant to the review.

Management of selection bias: Independent reviewers undertook investigation of all data sources to ensure a comprehensive scope of the search, and to reduce errors/bias in accessing or identifying the evidence.

Assessment of the methodological quality

A standard process was followed to critically appraise the included secondary literature for methodological quality.

Clinical guidelines were critically appraised using the Appraisal of Guidelines Research and Evaluation (AGREE) instrument (AGREE Collaboration, 2001). Two reviewers undertook independent appraisal and the scores were standardized into a single percentage score as detailed in the instrument guide (AGREE Collaboration, 2003). A high quality guideline should have high percentage scores across all domains of the AGREE tool. This assures readers that the guideline processes were well constructed and that the recommendations are believable and free of bias/external interference.

Systematic reviews and meta-analyses were critically appraised using the Critical Appraisal Skills Programme (CASP) tool for systematic reviews (CASP Tool; http://www.phru.nhs.uk/Doc_Links/S.Reviews%20Appraisal%20Tool.pdf). Two experienced reviewers independently critically appraised a random selection of 10% of the secondary evidence. They then shared their appraisal scores and discussed reasons for differences in scores. They agreed on a protocol for score assignment and interpretation of reporting, which underpinned assurances of reliability of scoring. The reviewers then independently reviewed the remainder of the secondary evidence, on an assumption that had both reviewers critically appraised each article, the same score would have been reached. Scores were reported numerically for critical appraisal items that attracted Yes/No answers (1. Clearly focused question? 2. Include the right type of study? 3. Identify all relevant studies? 4. Quality of study assessed? 5. If results have been combined, was it reasonable? 8. Results applicable to local situation? 9. All important outcomes considered? 10. Policy or practice change?). The remaining questions required qualitative text answers and were not readily summarized for statistical reporting. The questions with Yes answers were scored as 1, and each paper was given a score out of 8. The average score for each of the eight questions, and for each of the systematic reviews (and standard deviations), was calculated.

Data extraction, validation and reporting

Data were extracted using a purpose-built data extraction form that incorporated information on year and nature of publication, country of publication, sample descriptors (age, gender and ethnicity), population numbers, type of glaucoma, risk factors, prevalence and incidence data. A reference committee of Australian content experts (ophthalmologists, optometrists, GP, pharmacist, practice nurse) assisted the systematic review team by validating whether all relevant literature had been identified, and interpreted correctly. For this paper, all reports of glaucoma prevalence and incidence were highlighted, the data were summarized, and reasons for differences in reporting were considered.

Results

Search findings

The overall secondary literature search identified 65 systematic reviews and 14 clinical guidelines. Of these, 20 systematic reviews (reporting on over 230 primary studies) and six clinical guidelines reported on prevalence in glaucoma, and hence the findings from these studies are included in this aspect of the metasynthesis. To validate our decision to include secondary evidence that reported on prevalence and incidence of glaucoma, we checked the included primary references in these secondary evidence sources for their methodological design. Epidemiological studies are the appropriate research approach to report on incidence and prevalence of disease, and all the included primary studies reported epidemiologically appropriate designs.

Guidelines: The scores for each AGREE domain, as well as the average domain score for each included guideline for this paper, are provided in Table 1. The scores were not uniformly high across all domains for all guidelines, highlighting the variable quality of guideline construction.

Table 1 Appraisal of Guidelines Research and Evaluation critical appraisal scores

Systematic reviews: The overall average quality score for the 20 systematic reviews for the eight quantitative questions in the CASP tool was 5.3 (SD 1.9), which indicated the moderate quality overall of the reviews. Variable-sized average scores but similar standard deviations were found for each question (Q1 0.9 (SD 0.4), Q2 0.7 (SD 0.5), Q3 0.8 (SD 0.4), Q4 0.4 (SD 0.5), Q5 0.7 (SD 0.5), Q8 0.8 (SD 0.4), Q9 0.9 (SD 0.4), and Q10 0.5 (SD 0.5). The individual scores for each included paper are reported in Table 2.

Table 2 Relevant Critical Appraisal Skills Programme scores (Q 1–5, 8–10) (total 8)

Overview

Types of glaucoma

Reports of prevalence and incidence were found mostly for primary open-angle glaucoma (POAG), and primary angle-closure glaucoma (PACG). Prevalence data were largely missing for childhood and secondary glaucomas.

There was no standard definition of glaucoma, with examples of definitions from systematic reviews being:

  1. 1. Glaucoma is an eye affliction characterized by an increase in intraocular pressure (Amar, Reference Amar2006: 17).

  2. 2. Glaucoma is an optic nerve neuropathy that leads to progressive visual field loss (Fleming et al., Reference Fleming, Whitlock, Beil, Smit and Harris2005: 167).

  3. 3. Glaucoma describes a group of eye diseases, in which there is progressive damage to the optic nerve leading to impaired vision and blindness if untreated. The primary glaucomas (those that are not a consequence of other eye or systemic disease) can be classified as OAG or angle-closure glaucoma. These two types are distinguished by the anatomy of the anterior segment of the eye (Burr et al., Reference Burr, Mowatt, Hernández, Siddiqui, Cook, Lourenco, Ramsay, Vale, Fraser, Azuara-Blanco, Deeks, Cairns, Wormald, McPherson, Rabindranath and Grant2007: 3).

  4. 4. Glaucoma is a group of related conditions characterised by optic nerve damage, nerve layer fibre defects and visual field loss and is generally associated with high intraocular pressure (Schmier et al., Reference Schmier, Halpern and Jones2007: 288).

  5. 5. Glaucoma refers to a multifactorial disease characterized by a progressive optic neuropathy followed by gradual visual field loss. Elevated intraocular pressure (IOP), which previously was part of the definition of glaucoma, is now recognized as the major risk factor for the development of the disease (Costa et al., Reference Costa, Harris, Stefansson, Flammer, Krieglstein, Orzalesi, Heijl, Renard and Serra2003: 770).

Whilst many systematic reviews and clinical guidelines report on, or predict, actual numbers of people who may suffer glaucoma, these numbers are generally meaningless without a standard comparator. For example, ‘an estimated 2.5 million Americans have open angle glaucoma’, (American Optometric Association, 2002: 7) and glaucoma ‘affects >2 million people in the US, and the incidence is expected to exceed 3 million by 2020’ (Schmier et al., Reference Schmier, Halpern and Jones2007: 287). Without a comparator, the true nature of the severity of glaucoma is not able to be determined.

Internationalization

Of the secondary evidence included in this metasynthesis, the majority was internationally focused, with only one systematic review (Madden et al., Reference Madden, Simmons, McCarty, Khan and Taylor2002) reporting specifically on Australian data. Another systematic review (Burr et al., Reference Burr, Mowatt, Hernández, Siddiqui, Cook, Lourenco, Ramsay, Vale, Fraser, Azuara-Blanco, Deeks, Cairns, Wormald, McPherson, Rabindranath and Grant2007) included Australian data from two studies (Mitchell et al., Reference Mitchell, Smith, Attebo and Healey1996; Weih et al., Reference Weih, Nanjan, McCrty and Taylor2001); however, the data were reported as population-based prevalence, and not stratified by age, gender or other descriptor. The expert reference committee recommended the inclusion of Australian primary evidence: the Blue Mountains Eye Study (BMES) (Mitchell et al., Reference Mitchell, Smith, Attebo and Healey1996), the Visual Impairment Project (VIP) (Weih et al., Reference Weih, Nanjan, McCrty and Taylor2001) and data from the Australian Institute of Health and Welfare (AIHW) (2005) and the Australian Bureau of Statistics (ABS) (2004), in order to provide more comprehensive Australian glaucoma prevalence/incidence findings.

We summarized the metasynthesis findings into categories of ethnicity, age, specific populations and glaucoma subtypes, in order to make sense of the ways in which glaucoma prevalence and incidence of glaucoma was reported.

Terminology differed regarding calculation of prevalence and incidence. In most instances, it was unstated. The most useful definition was from Burr et al. (Reference Burr, Mowatt, Hernández, Siddiqui, Cook, Lourenco, Ramsay, Vale, Fraser, Azuara-Blanco, Deeks, Cairns, Wormald, McPherson, Rabindranath and Grant2007: 26): Methods of calculation of prevalence ‘as the number of participants diagnosed with glaucoma divided by the number of participants screened’. These researchers reported calculating incidence for each age category ‘as the mean and range for cases per 100 000 years at risk……… As an example, incidence estimates for the UK were determined by dividing the number of cases newly diagnosed by the number of people at risk (population data were obtained from the 2001 UK Census)’.

Ethnicity was reported in both very general terms such as black and white, and in very specific ethnic terms such as East Greenlandic Inuit or Chinese. Data were either country-specific or for a group of countries (such as western, worldwide, industrialized).

Table 3 compares data between ethnic groups with respect to risks of different types of glaucoma. This table highlights the variability of reports of prevalence with respect to ethnicity. Schmier et al. (Reference Schmier, Halpern and Jones2007: 288) reported that the prevalence of POAG is higher among African Americans and Hispanics/Latinos than among other ethnic groups. Conversely prevalence of PACG is reported to be highest among those of Asian or Inuit heritage, with rates in these populations reported to be three- to ten-fold higher than in other ethnic groups (Friedman and Vedula, Reference Friedman and Vedula2006; Schmier et al., Reference Schmier, Halpern and Jones2007).

Table 3 Differential ethnic risks of glaucoma subtypes

PACG = primary-angle closure glaucoma; OAG = open-angle glaucoma; POAG = primary OAG; RR = relative risk; CI = confidence interval.

Table 4 reports on the incidence of glaucoma with respect to different populations. This table highlights the consistency across studies in the decreased risk of white (European) populations compared with other ethnic groups.

Table 4 Incidence within specific populations for glaucoma subtypes

OAG = open-angle glaucoma; PCG = primary closed glaucoma.

Age was variably classified into five- or ten-year ranges, as well as undefined descriptors such as ‘adult’ or ‘infant’. There was a large volume of secondary evidence reporting on the influence of age on open-angle glaucoma (OAG) and POAG (see Table 5). Plosker and Keam (Reference Plosker and Keam2006) indicated that overall, there was four times the risk of glaucoma for people aged 80 or more compared with people younger than 50 years. In the Australian VIP study, this difference was substantially bigger being 17 times more likely that, participants aged 80 years and older were likely to have glaucoma than participants less than 50 years of age (Weih et al., Reference Weih, Nanjan, McCrty and Taylor2001: 1969).

Table 5 Prevalence of age-based glaucoma within the general population

OAG = open-angle glaucoma; POAG = primary OAG; Glaucoma = subtype not specified; NTG = normal tension glaucoma.

Table 6 reports on the contributing influence that both age and ethnicity have on the prevalence of glaucoma within specific populations. For instance, the Burr et al. (Reference Burr, Mowatt, Hernández, Siddiqui, Cook, Lourenco, Ramsay, Vale, Fraser, Azuara-Blanco, Deeks, Cairns, Wormald, McPherson, Rabindranath and Grant2007) data show the prevalence of glaucoma in the American black population aged 70–79 years as 9.15%. This is four times greater than the American white population aged 80 or more. This is further supported by Schmier et al. (Reference Schmier, Halpern and Jones2007) who report age-adjusted prevalence rates for POAG were four to five times higher in blacks as compared with whites.

Table 6 Prevalence of open-angle glaucoma (OAG) and primary OAG (POAG) within different ethnic and age populations

Table 7 reports on the Australian-specific age-related glaucoma data. The population prevalence of glaucoma from these studies ranges from 1.7% to 2.5%.

Table 7 Prevalence of glaucoma in Australian studies (clinical and self-reported) (Australian Institute of Health and Welfare (AIHW), 2005)

BMES = Blue Mountains Eye Study; VIP = Visual Impairment Project; NHS = National Health Service.

Location: Madden et al. (Reference Madden, Simmons, McCarty, Khan and Taylor2002) conducted a systematic review of eye health in rural Australia, finding little relevant published information. These authors used but did not define the terms ‘possible glaucoma’ and ‘probable glaucoma’. They reported the prevalence of various eye conditions from the VIP, and found a significantly elevated risk of possible glaucoma in rural areas (rural prevalence 1.8%, urban prevalence 1.2%), odds ratio of 1.6 (95% CI (confidence interval) 1.1, 2.2). Probable glaucoma had a rural prevalence of 1.02% (urban prevalence of 0.49%) again demonstrating a significantly elevated odds with rural living (odds ratio 1.6 (95% CI 1.1, 2.5)).

Australian Aboriginal and Torres Strait Islanders: The ABS (2004) National Aboriginal and Torres Strait Islander Health Survey 2004–05 provided data on long-term eye/sight problems. Eye/sight problems were reported in 30% of the population, compared with a report, three years earlier (2001), of 29%. Consistent with results from the 2001 survey, eye/sight problems were the most commonly reported long-term health condition among Aboriginal and Torres Strait Islander people in 2004–2005. Diseases of the eye were broken into the following conditions: cataract, short sighted/myopia, long sighted/hyperopia, blindness (complete/partial) and other diseases of the eye and adnexa. Glaucoma is not a condition specified in the breakdown; however, it is likely to fall within the ‘other diseases of the eye and adnexa’ category. In 2001, 7% of the population reported ‘other diseases of the eye and adnexa’, while in 2004 this had declined to 6%.

Open-angle glaucoma: Table 8 reports on the per-age group per 100 000 incidence of open-angle glaucoma. The reported incidence rates vary widely even between the same age groups across the ‘general’ population. For example, the general incidence rate in 60 year old population is reported as 60 and also 120 per 100 000. This variance could possibly be due to the use of different definitions of glaucoma, which could affect whether a diagnosis of glaucoma is made.

Table 8 Incidence of open-angle glaucoma within the general population

Angle-closure glaucoma: Table 9 reports on the prevalence of angle-closure glaucoma, within specific populations. The table illustrates the association between ethnicity and risk of angle-closure glaucoma. Inuit adults have a higher prevalence compared to other ethnic groups including Asian, European and African groups (American Academy of Ophthalmology (AAO), 2005). The SEAGIG (2003) reports the incidence of acute angle-closure glaucoma, within different ethnic groups in Finland and Singapore. It was found that Chinese have a higher incidence of acute angle-closure glaucoma (15.5 per 100 000) than other ethnic groups (4.7–6.7 per 100 000) (SEAGIG, 2003).

Table 9 Prevalence of angle closure glaucoma within specific populations

Discussion

Overview

Our metasynthesis approach to summarizing the literature for the question regarding glaucoma prevalence highlighted the efficiencies of using existing secondary evidence, which had already summarized a large number of recent primary studies. Metasynthesis of secondary evidence is becoming an increasingly common technical approach, which efficiently capitalizes on existing secondary evidence research. In this case, despite identifying 20 systematic reviews and six clinical guidelines (providing access to at least 230 primary studies published in the past five years), the heterogeneity of the included reviews precluded meta-analysis. This metasynthesis found a wealth of international publication interest in glaucoma; however, there was little consistency in definitions of glaucoma or risk factors, methods of reporting or prevalence estimates. None of the included systematic reviews dealt only with the topic of prevalence of glaucoma. This information was often reported as a precursor to other information related to glaucoma diagnosis or risk identification.

Glaucoma definitions

There is no one definitive definition of glaucoma that is consistently used in the papers included in this review. This appears largely due to the number of subtypes and separate classifications of glaucoma involved. For example, the Japan Glaucoma Society (JGS) (2004) classifies glaucoma into: primary glaucoma, in which no other cause of elevated intraocular pressure (IOP) is present; secondary glaucoma, in which the elevation in IOP results from other ocular diseases, ocular trauma, systemic diseases or drug use; and developmental glaucoma, in which the elevation in IOP results from developmental anomalies in the anterior chamber angle. This can cause glaucomatous damage to the optic nerve head and prevents visual development. Alternatively, in Henness et al. (Reference Henness, Harrison and Keating2007) systematic review, glaucoma is classified into three broad categories: congenital glaucoma; open-angle glaucoma; and angle-closure glaucoma, with primary and secondary types within each category.

Not all prevalence studies of glaucoma separate primary and secondary glaucoma in a consistent fashion, if they have done so at all. Debate remains over inclusion of subtypes such as ocular hypertension and normal tension glaucoma under the broader term of POAG.

Foster et al. (Reference Foster, Buhrmann, Quigley and Johnson2002) highlight the effect that the selection of glaucoma definition and the population from which the data is derived, can have on the accuracy of reporting prevalence and incidence. Different definitions of glaucoma can result in under-estimation or over-estimation of the prevalence and incidence of glaucoma and its subtypes. It can also result in non-diagnosis of glaucoma. Given the estimated percentage of the population with undiagnosed glaucoma, this would seem to be of concern. The lack of clear information on prevalence and incidence, will impact on policymakers’ ability to estimate resource use to appropriately diagnose and manage glaucoma in future populations.

Different population descriptors

There were no standard population descriptors (age, ethnicity, country) utilized by the primary studies included in the published systematic reviews, or in the guidelines identified in this search. As a consequence, it was difficult to make comparisons between studies, or to propose consistent figures with respect to glaucoma prevalence, incidence or risk in specific populations.

Age classification

In general, in white populations around the world, the prevalence and incidence of glaucoma increases significantly with adult ages (Mitchell et al., Reference Mitchell, Smith, Attebo and Healey1996; Weih et al., Reference Weih, Nanjan, McCrty and Taylor2001; Burr et al., Reference Burr, Mowatt, Hernández, Siddiqui, Cook, Lourenco, Ramsay, Vale, Fraser, Azuara-Blanco, Deeks, Cairns, Wormald, McPherson, Rabindranath and Grant2007). Burr et al. (Reference Burr, Mowatt, Hernández, Siddiqui, Cook, Lourenco, Ramsay, Vale, Fraser, Azuara-Blanco, Deeks, Cairns, Wormald, McPherson, Rabindranath and Grant2007) and Plosker and Keam (Reference Plosker and Keam2006) both report that people aged 70+ years have approximately three times greater risk of developing glaucoma than people aged 40 years. However, in the VIP, an Australian study, this difference was substantially bigger. Weih et al. (Reference Weih, Nanjan, McCrty and Taylor2001: 1969) reported participants aged 80 years and older were 17 times more likely to have glaucoma than participants less than 50 years of age.

Prevalence and incidence rates were often reported by age classifications, however, without a consistent reference classification. For example, some studies used five-year ranges, whilst others used 10-year ranges, that is, 45–49, 40–49 and 80+ or 90+. Glaucoma was also reported with variable prevalence, usually related to different age groups (for instance, under 40 years, or 50 years, for younger age glaucoma, and 60 years, or 70 years, for older glaucoma). Thus it was not possible to accurately compare the prevalence rates between age groups. Some studies used the descriptors ‘adult’ and ‘infant’, without defining what age brackets these terms encompassed. Two systematic reviews reported age-adjusted prevalence data. Einarson et al. (Reference Einarson, Vicente, Machado, Covert, Trope and Iskedjian2006; citing Coleman (1999), Leske et al. (1994)) and Schmier et al. (Reference Schmier, Halpern and Jones2007) systematic reviews both reported specific age-adjusted prevalence rates for POAG. Age-adjusted prevalence data have limited application in the clinical sense, as it is a mechanism for providing comparisons across the population as a whole. It is more often used in the research environment. A clinician is more interested in understanding what the actual risk is, for (say) a 70-year-old patient, with whom they are consulting. This lack of consistency in classifying age makes it difficult to compare results, as well as constraining translation of research evidence into clinical practice.

Country classification

Prevalence and incidence rates were reported using countries as population descriptors. This was either as individual country/countries or as a grouping of countries. Often it was not clear which countries were included in a group. For example under ‘worldwide’, there was no explanation as to how many and which countries data had been collected from. It was also not clear whether the data collected were proportional (ie, had data been collected from each continent). It also seems unlikely that data were collected from all 195 countries; therefore, the appropriateness of ‘worldwide’ as a descriptor is questioned. Similarly, there is no internationally agreed standard terminology for some of the descriptors used (industrialized, Western) and thus different people could interpret the generalizability and applicability of the data differently.

Ethnicity classification

There was no clarity on ethnic classifications. Some classifications were general (black, white or Asian), without any details on ethnic inclusions, whilst others were very specific to a small population, such as the East Greenlandic Inuit. Given the diversity of the included population under generic ethnic terms, these data are unlikely to be as generalizable or applicable as data that are collected with specified ethnicity.

Despite concerns regarding definition and diagnosis, the prevalence of glaucoma for black and Asian (unspecified country of origin) populations is elevated compared with white populations, with most reports suggesting approximately a three-fold increase. The same differential is reported for incidence in black populations compared with white. The exact racial and ethnic components included within the umbrella terms ‘black’ and ‘white’ were not uniformly specified within the secondary evidence. In the majority of cases where some specification was made, black referred to those of African American origin and white to those of Caucasian origin. There was nothing to imply that black populations included indigenous populations as relevant to the Australian context.

Open-angle glaucoma

Overall prevalence for glaucoma of between 1–4% is commonly reported worldwide, although the prevalence and incidence of POAG and general OAG were variably reported. Prevalence is closely linked to age and ethnicity of the population. Open-angle glaucoma is the most common form of glaucoma and accounts for 75% to 95% of primary glaucomas, except in people of Eastern Asian (Mongoloid) descent (Burr et al., Reference Burr, Mowatt, Hernández, Siddiqui, Cook, Lourenco, Ramsay, Vale, Fraser, Azuara-Blanco, Deeks, Cairns, Wormald, McPherson, Rabindranath and Grant2007). There appears to be consistency for the prevalence reported within the subgroups and general population, across most of the literature. However, reporting the incidence of OAG in the general population varied considerably (see Table 8).

Angle-closure glaucoma

There is little information on the incidence and prevalence of angle-closure glaucoma. This lack of data should not undermine the importance of angle-closure glaucoma, as in China, PACG is reported to be responsible for >90% of bilateral glaucoma blindness (Saw et al., Reference Saw, Gazzard and Friedman2003). Foster et al. (Reference Foster, Buhrmann, Quigley and Johnson2002) emphasize that current PACG classification is largely based on clinical observations in European derived people, among whom the condition is rare. While the acute, symptomatic phase is dramatic, it occurs in only a minority of those with PACG diagnosed in population-based surveys in African and Asian settings.

Childhood and secondary glaucomas

There was only one systematic review (Moore and Nischal, Reference Moore and Nischal2007) that considered the incidence data on childhood primary congenital glaucoma. However, this review did not discuss prevalence data. Prevalence and incidence data for secondary glaucoma was not reported in the included systematic reviews for this review. This highlights that there is a possible gap in available evidence for this classification of glaucoma. It is also probable that the varying definitions of glaucoma have affected the diagnosis of secondary glaucoma, thereby impacting on available prevalence and incidence data.

Specifically for Australia

There was only one systematic review that focused specifically on Australia (Madden et al., Reference Madden, Simmons, McCarty, Khan and Taylor2002), which for glaucoma prevalence was only reported from the VIP study. Burr et al. (Reference Burr, Mowatt, Hernández, Siddiqui, Cook, Lourenco, Ramsay, Vale, Fraser, Azuara-Blanco, Deeks, Cairns, Wormald, McPherson, Rabindranath and Grant2007) included non-age stratified prevalence data from the VIP and BMES studies. These two primary Australian studies were also included in our review, as well as an ABS (2004) survey and AIHW (2005) report in order to collate current Australian prevalence information.

The two landmark population studies performed in Australia (BMES, VIP) provide useful data on the prevalence of eye diseases and visual impairment. However, they were conducted predominantly on white people and prevalence data from other ethnic groups were not provided. No people with an Aboriginal or Torres Strait Islander ancestry were involved in either study (Mitchell et al., Reference Mitchell, Smith, Attebo and Healey1996; Weih et al., Reference Weih, Nanjan, McCrty and Taylor2001). Weih et al. (Reference Weih, Nanjan, McCrty and Taylor2001: 1969) in the ‘VIP study found an overall prevalence of definite (1.8%) or probable or definite (2.5%) glaucoma which is comparable with prevalence reported for other white populations’. Mitchell et al. (Reference Mitchell, Smith, Attebo and Healey1996: 1665) note that an ‘exponential increase in prevalence for glaucoma was found for increasing 10-year age groups’.

A key failing of these two studies in providing useful estimates of prevalence was the inclusion of ‘white’ people without further ethnic breakdown. Given the multicultural population of Australia, the generalizability of these findings across the entire Australian population should be questioned. Data regarding the prevalence and incidence of glaucoma within the indigenous population of Australia are limited. However, POAG does not appear to be an important cause of visual impairment in indigenous Australians (refer to ABS (2004)). Overall, Australian data on the prevalence of glaucoma appear to be comparable with the international prevalence rates for OAG in white populations (refer to Tables 57).

Comparison measures

Prevalence was always reported as percentages. However, the differing population descriptors made a synthesis of these estimates difficult. The risk of glaucoma was often reported using quantified (ie, four-fold higher) or unquantified (ie, increased) comparisons or risk ratios between different ethnic groups (refer to Table 3).

Data collection

The method of data collection can impact on the accuracy of the glaucoma diagnosis. Some of the Australian data were self-reported. In one survey, ‘vision loss was defined by self-report as blindness and other vision disturbances which cannot be corrected by spectacles, and is a long-term sight problem which has lasted or is expected to last for 6 months or more’ (AIHW, 2005: 30), whereas in another survey, ‘vision loss was defined by self-report as total or partial loss of sight, which cannot be corrected by spectacles’ (AIHW, 2005: 30). Self-reported data can be questionable depending on whether definitions are provided to or determined by participants and on the type, number and complexity of the questions asked. Foster et al. (Reference Foster, Buhrmann, Quigley and Johnson2002) state the accuracy of prevalence and incidence data derived from ‘self-reported’ cases of glaucoma needs to be considered, given the likelihood of differing definitions of glaucoma held by clinicians as well as the population.

Also of note was that many of the systematic reviews were based on the epidemiology data from papers often published up to 10 years earlier. Thus, even from recent reviews it was difficult to obtain a current and consistent view of prevalence. For example, in the Moore and Nischal (Reference Moore and Nischal2007) review, the incidence data on childhood primary congenital glaucoma came from a study published in 1980, whilst in the Rolim de Moura et al. (Reference Rolim de Moura, Paranhos and Wormald2007) review, the prevalence data for POAG were based on studies reported in 1983, 1991, 1994, 1997, 1998 and 2000.

Conclusion

There is a lack of consistent summary evidence on the prevalence and incidence of glaucoma internationally, although the available secondary evidence suggests that it is of the magnitude 1–4%. Variability in reporting glaucoma epidemiology appears to reflect international differences in disease and population definitions, disease prevalence measures and data capture methods. There is a clear need for worldwide agreement on standard epidemiological descriptors of glaucoma, using standard population frameworks, standard terminology and standard age groups. Ethnic and age differences are reported as consistent risk factors related to glaucoma type and prevalence, although these are variably defined. The key clinical and methodological issues that need to be considered in future research include clearly defined population descriptors and the use of standard glaucoma definitions and classifications to enable meaningful comparisons to be made, increasing the believability of the data reported.

Acknowledgement

The authors wish to acknowledge that funding was provided by the Australian National Health and Medical Research Council (NHMRC).

Appendix 1

Identified keywords

‘Glaucoma’ AND

Databases searched

References

AGREE Collaboration. 2001: Appraisal of guidelines for research and evaluation (AGREE) instrument. Retrieved 18 February 2008 from http://www.agreecollaboration.comGoogle Scholar
AGREE Collaboration. 2003: Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Quality and Safety in Health Care 12, 823.Google Scholar
Alexander, C.L., Miller, S.J.Abel, S.R. 2002: Prostaglandin analog treatment of glaucoma and ocular hypertension. Annals of Pharmacotherapy 36, 504511.CrossRefGoogle ScholarPubMed
Amar, M.B. 2006: Cannabinoids in medicine: a review of their therapeutic potential. Journal of Ethnopharmacology 105, 125.CrossRefGoogle Scholar
American Academy of Ophthalmology (AAO). 2005: Primary angle closure preferred practice pattern. San Franciso, CA: American Academy of Ophthalmology.Google Scholar
American Optometric Association (AOA). 2002: Optometric clinical practice guideline: care of the patient with open angle glaucoma, second edition. St Louis, MO: American Optometric Association.Google Scholar
Australian Institute of Health and Welfare (AIHW). 2005: Vision problems among older Australians. AIHW Bulletin-27. Retrieved 8 August 2008 from http://www.aihw.gov.au/publications/index.cfmGoogle Scholar
Australian Bureau of Statistics (ABS). 2004: National Aboriginal and Torres Strait Islander Health Survey 2004–05. Retrieved 28 May 2008 from http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4715.0Main+Features12004-05?OpenDocumentGoogle Scholar
Burr, J., Azuara-Blanco, A.Avenell, A. 2004: Medical versus surgical interventions for open angle glaucoma. Cochrane Database of Systematic Reviews 8CD004399, 10.1002/14651858.CD004399.pub2.CrossRefGoogle Scholar
Burr, J.M., Mowatt, G., Hernández, R., Siddiqui, M., Cook, J., Lourenco, T., Ramsay, C., Vale, L., Fraser, C., Azuara-Blanco, A., Deeks, J., Cairns, J., Wormald, R., McPherson, S., Rabindranath, K.Grant, A. 2007: The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technology Assessments 11, 1206.Google ScholarPubMed
Costa, V.P., Harris, A., Stefansson, E., Flammer, J., Krieglstein, G.K., Orzalesi, N., Heijl, A., Renard, J.P.Serra, L.M. 2003: The effects of antiglaucoma and systemic medications on ocular blood flow. Progress in Retinal and Eye Research 22, 769805.CrossRefGoogle ScholarPubMed
Denis, P., Lafuma, A., Khoshnood, B., Mimaud, V.Berdeaux, G. 2007: A meta-analysis of topical prostaglandin analogues intraocular pressure lowering in glaucoma therapy. Current Medical Research and Opinion 23, 601608.CrossRefGoogle ScholarPubMed
Einarson, T.R., Vicente, C., Machado, M., Covert, D., Trope, G.E.Iskedjian, M. 2006: Screening for glaucoma in Canada: a systematic review of the literature. Canadian Journal of Ophthalmology 41, 709721.CrossRefGoogle Scholar
Fleming, C., Whitlock, E.P., Beil, T., Smit, B.Harris, R.P. 2005: Screening for primary open-angle glaucoma in the primary care setting: an update for the US preventive services task force. Annals of Family Medicine 3, 167170.CrossRefGoogle ScholarPubMed
Foster, P.J., Buhrmann, R., Quigley, H.A.Johnson, G.J. 2002: The definition and classification of glaucoma in prevalence surveys. British Journal of Ophthalmology 86, 238242.CrossRefGoogle ScholarPubMed
Friedman, D.S.Vedula, S.S. 2006: Lens extraction for chronic angle-closure glaucoma. Cochrane Database of Systematic Reviews. Issue 13 Art. No. CD005555.CrossRefGoogle ScholarPubMed
Fung, A.T., Reid, S.E., Jones, M.P., Healey, P.R., McCluskey, P.J.Craig, J.C. 2007: Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. British Journal of Ophthalmology 91, 6268.CrossRefGoogle ScholarPubMed
Hatt, S., Wormald, R.Burr, J. 2006: Screening for prevention of optic nerve damage due to chronic open angle glaucoma. Cochrane Database of Systematic Reviews. Issue 4 Art. No. CD006129.CrossRefGoogle ScholarPubMed
Henness, S., Harrison, T.S.Keating, G.M. 2007: Ocular carteolol – a review of its use in the management of glaucoma and ocular hypertension. Drugs & Aging 24, 509528.CrossRefGoogle ScholarPubMed
Holmstrom, S., Buchholz, P., Walt, J., Wickstrom, J.Aagren, M. 2005: Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Current Medical Research and Opinion 21, 18751883.CrossRefGoogle ScholarPubMed
Japan Glaucoma Society (JGS). 2004: Guidelines for glaucoma. Tokyo: Japan Glaucoma Society.Google Scholar
Law, S.K.Li, T. 2007: Acupuncture for glaucoma. Cochrane Database of Systematic Reviews. Issue 4 Art. No. CD006030.CrossRefGoogle ScholarPubMed
Madden, A.C., Simmons, D., McCarty, C.A., Khan, M.A.Taylor, H.R. 2002: Eye health in rural Australia. Clinical and Experimental Ophthalmology 30, 316321.CrossRefGoogle ScholarPubMed
Maier, P.C., Funk, J., Schwarzer, G., Antes, G.Falck-Ytter, Y.T. 2005: Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. British Medical Journal 331, 134139.CrossRefGoogle ScholarPubMed
Mitchell, P., Smith, W., Attebo, K.Healey, P. 1996: Prevalence of open-angle glaucoma in Australia: the Blue Mountains eye study. Ophthalmology 103, 16611669.CrossRefGoogle ScholarPubMed
Moore, W.Nischal, K.K. 2007: Pharmacologic management of glaucoma in childhood. Pediatric Drugs 9, 7179.CrossRefGoogle ScholarPubMed
Moher, D., Klassen, T.P., Schulz, K.F.Berlin, J.A. 2000: What contributions do languages other than English make on the results of meta-analyses? Journal of Clinical Epidemiology 53, 964972.CrossRefGoogle ScholarPubMed
Moher, D., Pham, B., Lawson, M.L.Klassen, T.P. 2003: The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technology Assessment 7, 190.CrossRefGoogle ScholarPubMed
Møller, A.P.Jennions, M.D. 2001: Testing and adjusting for publication bias. Trends in Ecology & Evolution 16, 580586.CrossRefGoogle Scholar
National Health and Medical Research Council (NHMRC). 2005: NHMRC additional levels of evidence and grades for recommendations for developers of guidelines: stage 2 consultation. Retrieved 8 August 2008 from http://www.nhmrc.gov.au/guidelines/_files/Stage%202%20Consultation%20Levels%20and%20Grades.pdf, www.nhmrc.gov.auGoogle Scholar
Obstbaum, S.A., Cioffi, G.A., Krieglstein, G.K., Fennerty, M.B., Alm, A., Araie, M., Carassa, R.G., Greve, E.L., Hitchings, R.A., Kaufman, P.L., Kitazawa, Y., Pongpun, P.R., Susanna, R. JrWax, M.B.Zimmerman, T.J. 2004: Gold standard medical therapy for glaucoma: defining the criteria identifying measures for an evidence-based analysis. Clinical Therapeutics 26, 21022120.CrossRefGoogle ScholarPubMed
Plosker, G.L.Keam, S.J. 2006: Bimatoprost – a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension. PharmacoEconomics 24, 297314.CrossRefGoogle ScholarPubMed
Rolim de Moura, C., Paranhos, A. JrWormald, R. 2007: Laser trabeculoplasty for open angle glaucoma (review). Cochrane Database of Systematic Reviews. Issue 4 Art. No. CD003919.CrossRefGoogle Scholar
Rowe, S., MacLean, C.H.Shekelle, P.G. 2004: Preventing visual loss from chronic eye disease in primary care: scientific review. Journal of the American Medical Association 291, 14871495.CrossRefGoogle ScholarPubMed
Royal College of Ophthalmologists (RCO). 2004: Guidelines for the management of open angle glaucoma and ocular hypertension. London: Royal College of Ophthalmologists.Google Scholar
Saw, S.M., Gazzard, G.Friedman, D.S. 2003: Interventions for angle-closure glaucoma: an evidence-based update. Ophthalmology 110, 18691878.CrossRefGoogle ScholarPubMed
Schmier, J.K., Halpern, M.T.Jones, M.L. 2007: The economic implications of glaucoma – a literature review. PharmacoEconomics 25, 287308.CrossRefGoogle ScholarPubMed
South-East Asia Glaucoma Interest Group (SEAGIG). 2003: Asia Pacific glaucoma guidelines. Sydney: South-East Asia Glaucoma Interest Group.Google Scholar
Sycha, T., Vass, C., Findl, O., Bauer, P., Groke, I., Schmetterer, L.Eichler, H. 2003: Interventions for normal tension glaucoma. Cochrane Database of Systematic Reviews. Issue 1 Art. No. CD002222.CrossRefGoogle ScholarPubMed
US Preventive Services Task Force (USPSTF). 2005: Screening for glaucoma: recommendation statement. Rockville, MD: Agency for Healthcare Research and Quality, 1–16.Google Scholar
Weih, L., Nanjan, M., McCrty, C.Taylor, H. 2001: Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. Ophthalmology 108, 19661972.CrossRefGoogle ScholarPubMed
Figure 0

Table 1 Appraisal of Guidelines Research and Evaluation critical appraisal scores

Figure 1

Table 2 Relevant Critical Appraisal Skills Programme scores (Q 1–5, 8–10) (total 8)

Figure 2

Table 3 Differential ethnic risks of glaucoma subtypes

Figure 3

Table 4 Incidence within specific populations for glaucoma subtypes

Figure 4

Table 5 Prevalence of age-based glaucoma within the general population

Figure 5

Table 6 Prevalence of open-angle glaucoma (OAG) and primary OAG (POAG) within different ethnic and age populations

Figure 6

Table 7 Prevalence of glaucoma in Australian studies (clinical and self-reported) (Australian Institute of Health and Welfare (AIHW), 2005)

Figure 7

Table 8 Incidence of open-angle glaucoma within the general population

Figure 8

Table 9 Prevalence of angle closure glaucoma within specific populations